Becton, Dickinson and Company (BDX) Set to Announce Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX) will issue its quarterly earnings data before the market opens on Thursday, August 1st. Analysts expect the company to announce earnings of $3.31 per share for the quarter. Becton, Dickinson and Company has set its FY24 guidance at $12.95-13.15 EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The business had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. During the same quarter last year, the company posted $2.86 earnings per share. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. On average, analysts expect Becton, Dickinson and Company to post $13 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $241.98 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $284.48. The company’s 50-day simple moving average is $232.40 and its 200-day simple moving average is $236.20. The stock has a market capitalization of $69.93 billion, a price-to-earnings ratio of 53.30, a PEG ratio of 2.08 and a beta of 0.42.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be given a dividend of $0.95 per share. The ex-dividend date is Monday, September 9th. This represents a $3.80 annualized dividend and a dividend yield of 1.57%. Becton, Dickinson and Company’s payout ratio is 83.70%.

Analyst Ratings Changes

BDX has been the topic of several research analyst reports. Stifel Nicolaus increased their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Monday, July 15th. Barclays increased their price objective on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday, May 6th. Evercore ISI dropped their price objective on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Finally, Citigroup dropped their price objective on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $280.13.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 3,300 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $236.73, for a total value of $781,209.00. Following the sale, the executive vice president now owns 11,308 shares in the company, valued at $2,676,942.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Thomas J. Spoerel sold 300 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the transaction, the senior vice president now directly owns 1,976 shares in the company, valued at $472,876.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Roland Goette sold 3,300 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $236.73, for a total transaction of $781,209.00. Following the completion of the transaction, the executive vice president now owns 11,308 shares of the company’s stock, valued at $2,676,942.84. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,900 shares of company stock worth $1,634,112. 0.31% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.